<DOC>
	<DOCNO>NCT01289678</DOCNO>
	<brief_summary>Assess immunotherapy benefit interleukin-2 acute myelogenous leukemia treatment lymphocyte recovery .</brief_summary>
	<brief_title>Trial Daily Pulse Interleukin-2 With Famotidine Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Confirmed hematopathology diagnosis AML receive marrow suppressive treatment Total WBC recovery 500 mm3 prior IL2 treatment Platelet count least 20,000 mm3 prior start IL2 treatment Active infection control prior start IL2 treatment Stable systolic blood pressure &gt; 90mm Hg prior start IL2 treatment O2 saturation &gt; 90 % prior start treatment Stable cardiopulmonary status prior start IL2 treatment Serum creatinine &lt; equal 2.0 mg/dl Total bilirubin AST &lt; 3x upper limit normal Acute Promyelocytic Leukemia Active thrombocytopenic bleeding Cardiac ejection fraction 45 % Pregnancy and/or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>acute myelogenous leukemia</keyword>
	<keyword>interleukin-2</keyword>
</DOC>